XRCC1 and rectal cancer: The adjusted ORs for the XRCC1 Arg/Gln and Gln/Gln genotypes compared with the Arg/Arg genotype were not statistically significant (OR 0.60, 95%CI 0.28–1.30, p = 0.194 for colon cancer; OR 0.62, 95%CI 0.24–1.58, p = 0.315 for rectal cancer).Therefore, the cancer subsite-specific study indicated that the MUTYH Gln324His and the APEX1 Asp148Glu have a colon cancer-specific risk.